65,437 trials
Osteoarthritis of the Knee
Primary: Incidence and Severity of Adverse Events and Serious Adverse Events (Phase 1) — 0; 15 events
Stroke
Primary: Change in Accuracy of Naming Untrained Pictures (Philadelphia Naming Test (PNT)) Pre-treatment to 1 Week Post-treatment — 22.3; 18.5 score on a scale — p=0.54
COVID-19 · Cytokine Storm
Primary: Number of Outpatient Subject Hospitalizations — 0; 0 Participants
Urothelial Carcinoma · Bladder Cancer
Primary: Progression-free Survival (PFS) — 3.0; 5.4 months
Synkinesis
Primary: Change in Sunnybrook Facial Grading System (SFGS) Between Baseline and 4 Month Scoring — 0.29; 5.86 score on a scale
Mild Cognitive Impairment
Primary: Number of Participants With a Hypotensive Episode — 16; 4 Participants
Heart Failure · Congestive Heart Failure
Primary: Change in Whole Blood Volume — -1253; -784 mL — p=>0.05
Prostate Cancer · Castration-resistant Prostate Cancer · Castration-resistant Prostate Cancer Metastatic to Bone
Primary: Bone Scan Index — 2.90; 3.79 percentage of skeletal mass
Liver Transplantation
Primary: Renal Recovery/ Function — 28; 26 Participants
Malignant Glioma
Primary: Feasibility of Caregiver Enrollment in the Intervention: Percentage of Eligible Caregivers Who Agree to Participate in the Study of This Intervention — 21 Participants
Obesity, Childhood
Primary: Body Mass Index Percentile Score Change at 10 Weeks — 0.307; 1.755 Percentile — p=0.248
Hemodialysis Access Failure
Primary: Number of Participants With Target Lesion Primary Patency at 6 Months Post Procedure — 11 Participants
Major Depressive Disorder With Anxious Distress
Primary: Change From Baseline in Hamilton Depression Rating Scale-17 (HDRS-17) Total Score at Week 6 — -8.8; -9.4 Units on a scale — p=0.2494
Loiasis
Primary: Cross-reactive Antigenemia — 12 Participants
Hypertension · Diabetes · Cardiovascular Disease
Primary: Change in Cardiac Global Longitudinal Strain — -1.4; -1.74; -1.14 % systolic deformation